Int J Stem Cells.  2014 May;7(1):30-32.

Stem Cells and Niemann Pick Disease

Affiliations
  • 1Stamina Foundation, Italy. andolinamarino@gmail.com

Abstract

BACKGROUND AND OBJECTIVES
Niemann Pick A disease causes a progressive accumulation of sphyngomyelin in several organs and the survival of the patients is usually limited to three years. We describe the outcome of a patient suffering from Niemann Pick A disease, who first underwent an haploidentical bone marrow transplantation, and then intrathecal and I.V injections of mesenchymal cells.
METHODS AND RESULTS
While the outcome of bone marrow transplantation was a complete failure, one month after the treatment with the mesenchymal cells the patient improved from the psychomotor and the parenchymal storage perspective. When hypersplenism was solved platelets rose quickly from 20,000 to 120,000/microliter.
CONCLUSIONS
Therefore cellular therapy should be considered as a possible choice of treatment of NPA disease.

Keyword

Niemann Pick; Stem cells; Mesenchymal; Treatment

MeSH Terms

Bone Marrow Transplantation
Humans
Hypersplenism
Niemann-Pick Diseases*
Stem Cells*

Reference

References

1. Schuchman EH, Desnick RJ. Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies. Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited diseases. 8th ed. New York: McGraw Hill;2001. 3589–3611.
2. Schneider PB, Kennedy EP. Sphingomyelinase in normal human spleens and in spleens from subjects with Niemann-Pick disease. J Lipid Res. 1967. 8:202–209.
Article
3. Marathe S, Schissel SL, Yellin MJ, Beatini N, Mintzer R, Williams KJ, Tabas I. Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem. 1998. 273:4081–4088.
Article
4. Wiedemann HR, Gerken H, Graucob E, Hansen HG. Recognition of heterozygosity in sphingolipidoses. (Letter) Lancet. 1965. 285:1283. only. Note: Originally Volume I.
5. Rodriguez-Lafrasse C, Vanier MT. Sphingosylphosphorylcholine in Niemann-Pick disease brain: accumulation in type A but not in type B. Neurochem Res. 1999. 24:199–205.
6. Schuchman EH, Desnick RJ. Niemann–Pick diseases types A and B: acid sphingomyelinase deficiencies. Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. 7th ed. New York, NY: McGraw-Hill;1995. 2601–2624.
7. McGovern MM, Aron A, Brodie SE, Desnick RJ, Wasserstein MP. Natural history of Type A Niemann-Pick disease: possible endpoints for therapeutic trials. Neurology. 2006. 66:228–232.
Article
8. Guillemot N, Troadec C, de Villemeur TB, Clément A, Fauroux B. Lung disease in Niemann-Pick disease. Pediatr Pulmonol. 2007. 42:1207–1214.
Article
9. Scaggiante B, Pineschi A, Sustersich M, Andolina M, Agosti E, Romeo D. Successful therapy of Niemann-Pick disease by implantation of human amniotic membrane. Transplantation. 1987. 44:59–61.
Article
10. Lanfranchi A, Andolina M, Tettoni K, Porta F, Locatelli F, De Manzini A, Candotti F, Albertini A. Functional depletion of T cells by vincristine and methylprednisolone as an in vitro model for the prevention of graft versus host disease. Haematologica. 1992. 77:11–15.
11. Hefferan MP, Galik J, Kakinohana O, Sekerkova G, Santucci C, Marsala S, Navarro R, Hruska-Plochan M, Johe K, Feldman E, Cleveland DW, Marsala M. Human neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation. PLoS One. 2012. 7:e42614.
Article
12. Andolina M. Treatment of spinal muscolar atrophy with intrathecal mesenchymal cells. Int J Stem Cells. 2012. 5:73–75.
Article
Full Text Links
  • IJSC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr